I think there's a concern with the process, and again we go back to the outcome. I go to the bureau not being satisfied. The bureau prefers to negotiate consent agreements and they do that much more often than going to litigation.
If I look at the bureau's not accepting Videotron as a remedy buyer, that's a red flag to me. Any competitor that is dependent on another competitor for key elements of its expansion plan or its competitive potential is at risk. That goes for companies beyond Videotron, including what Globalive is proposing. The process—